Viewing Study NCT01538992


Ignite Creation Date: 2025-12-24 @ 3:24 PM
Ignite Modification Date: 2026-01-01 @ 12:49 PM
Study NCT ID: NCT01538992
Status: WITHDRAWN
Last Update Posted: 2013-07-24
First Post: 2012-02-16
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Renal Denervation in Patients With Advanced Heart Failure
Sponsor: Bursa Postgraduate Hospital
Organization:

Study Overview

Official Title: Phase 3 Study of Renal Denervation That Improves Symptoms of Heart Failure and Enhances Life Quality in Advanced Heart Failure
Status: WITHDRAWN
Status Verified Date: 2013-07
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: we could not fined enough patients for the study
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: Sympathetic system has important role occurrence of symptoms in heart failure. Renal denervation that is ablated some of sympathetic nerves is affected pathology of heart failure. This interventional therapy improves symptoms and life quality.
Detailed Description: Primary Outcome Measures:

• Safety of Renal Denervation in Heart Failure patients as measured by Adverse Events

Secondary Outcome Measures:

• Ventricular function,NYHA functional Class, 6 min walking test, biochemical test and Renal function as measured by Glomerular Filtration Rate (GFR)

Eligibility Patients population: Volunteers, NYHA Class III-IV heart failure patients. Ages Eligible for Study: 18 Years to 85 Years Genders Eligible for Study: Both Accepts Healthy Volunteers: No

Study Oversight

Has Oversight DMC: False
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: